Abstract：
Matrix Gla protein (MGP) and trichorhinophalangeal syndrome type 1 (TRPS1) have recently emerged as novel breast-specific immunohistochemical (IHC) markers, particularly for triple-negative breast cancer (TNBC) and metaplastic carcinoma. The present study aimed to validate and compare the expression of MGP, TRPS1 and GATA binding protein 3 (GATA3) in metastatic breast carcinoma (MBC), invasive breast carcinoma (IBC) with special features, including special types of invasive breast carcinoma (IBC-STs) and invasive breast carcinoma of no special type with unique features, and mammary and non-mammary salivary gland-type tumours (SGTs). Among all enrolled cases, MGP, TRPS1 and GATA3 had comparable high positivity for ER/PR-positive (p=0.148) and HER2-positive (p=0.310) breast carcinoma (BC), while GATA3 positivity was significantly lower in TNBC (p<0.001). Similarly, the positive rates of MGP and TRPS1 in MBCs (99.4%), were higher than in GATA3 (90.9%, p<0.001). Among the IBC-STs, 98.4% of invasive lobular carcinomas (ILCs) were positive for all three markers. Among neuroendocrine tumours (NTs), all cases were positive for TRPS1 and GATA3, while MGP positivity was relatively low (81.8%, p=0.313). In the neuroendocrine carcinoma (NC) subgroup, all cases were positive for GATA3 and MGP, while one case was negative for TRPS1. All carcinomas with apocrine differentiation (APOs) were positive for GATA3 and MGP, while only 60% of the cases demonstrated moderate staining for TRPS1. Among mammary SGTs, MGP demonstrated the highest positivity (100%), followed by TRPS1 (96.0%) and GATA3 (72.0%). Positive staining for these markers was also frequently observed in non-mammary SGTs. Our findings further validate the high sensitivity of MGP and TRPS1 in MBCs, IBC-STs, and breast SGTs. However, none of these markers are capable of distinguishing between mammary and non-mammary SGTs.
摘要：
基质Gla蛋白（MGP）和1型三鼻咽综合征（TRPS1）最近已成为新的乳腺特异性免疫组织化学（IHC）标记，特别是三阴性乳腺癌（TNBC）和化生性癌。本研究旨在验证和比较MGP的表达，TRPS1和GATA结合蛋白3（GATA3）在转移性乳腺癌（MBC）中，具有特殊特征的浸润性乳腺癌（IBC），包括特殊类型的浸润性乳腺癌(IBC-STs)和具有独特特征的非特殊类型的浸润性乳腺癌,乳腺和非乳腺唾液腺型肿瘤（SGT）。在所有登记的病例中，MGP,TRPS1和GATA3对ER/PR阳性（p=0.148）和HER2阳性（p=0.310）乳腺癌（BC）具有相当高的阳性，而GATA3阳性在TNBC中显著降低(p<0.001)。同样，MBCs中MGP和TRPS1的阳性率（99.4%），高于GATA3(90.9%，p<0.001)。在IBC-ST中，98.4％的浸润性小叶癌（ILC）对所有三种标志物均为阳性。在神经内分泌肿瘤(NTs)中，所有病例的TRPS1和GATA3均为阳性，而MGP阳性相对较低（81.8%，p=0.313）。在神经内分泌癌（NC）亚组中，所有病例均为GATA3和MGP阳性，1例TRPS1阴性。所有伴有顶腺分泌分化（APO）的癌GATA3和MGP均为阳性，而仅60%的病例显示TRPS1中度染色。在乳腺SGT中，MGP表现出最高的积极性(100%)，其次是TRPS1（96.0%）和GATA3（72.0%）。在非乳腺SGT中也经常观察到这些标记的阳性染色。我们的发现进一步验证了MGP和TRPS1在MBCs中的高灵敏度，IBC-ST,和乳房SGTs。然而,这些标记都不能区分乳腺和非乳腺SGT。
